Genotyping single nucleotide polymorphisms for allele-selective therapy in Huntington disease
Open Access
- 1 June 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology Genetics
- Vol. 6 (3), e430
- https://doi.org/10.1212/nxg.0000000000000430
Abstract
Background The huntingtin gene (HTT) pathogenic cytosine-adenine-guanine (CAG) repeat expansion responsible for Huntington disease (HD) is phased with single nucleotide polymorphisms (SNPs), providing targets for allele-selective treatments. Objective This prospective observational study defined the frequency at which rs362307 (SNP1) or rs362331 (SNP2) was found on the same allele with pathogenic CAG expansions. Methods Across 7 US sites, 202 individuals with HD provided blood samples that were processed centrally to determine the number and size of CAG repeats, presence and heterozygosity of SNPs, and whether SNPs were present on the mutant HTT allele using long-read sequencing and phasing. Results Heterozygosity of SNP1 and/or SNP2 was identified in 146 (72%) individuals. The 2 polymorphisms were associated only with the mHTT allele in 61% (95% high density interval: 55%, 67%) of individuals. Conclusions These results are consistent with previous reports and demonstrate the feasibility of genotyping, phasing, and targeting of HTT SNPs for personalized treatment of HD.Keywords
This publication has 10 references indexed in Scilit:
- Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotidesNature Biotechnology, 2017
- Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasisPLoS Genetics, 2017
- Personalized gene silencing therapeutics for Huntington diseaseClinical Genetics, 2014
- A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interferenceExperimental Neurology, 2009
- Five siRNAs Targeting Three SNPs May Provide Therapy for Three-Quarters of Huntington's Disease PatientsCurrent Biology, 2009
- CAG Expansion in the Huntington Disease Gene Is Associated with a Specific and Targetable Predisposing HaplogroupAmerican Journal of Human Genetics, 2009
- Identification and Allele-Specific Silencing of the Mutant Huntingtin Allele in Huntington's Disease Patient-Derived FibroblastsHuman Gene Therapy, 2008
- Wild‐type huntingtin protects neurons from excitotoxicityJournal of Neurochemistry, 2006
- Huntingtin Controls Neurotrophic Support and Survival of Neurons by Enhancing BDNF Vesicular Transport along MicrotubulesCell, 2004
- Unified Huntington's disease rating scale: Reliability and consistencyMovement Disorders, 1996